BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33622910)

  • 1. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Differentiated Thyroid Carcinoma Having Distant Metastasis: A Comparison With Thyroglobulin-doubling Rate and Tumor Volume-doubling Rate.
    Ito Y; Onoda N; Kihara M; Miya A; Miyauchi A
    In Vivo; 2021; 35(2):1125-1132. PubMed ID: 33622910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.
    Wassermann J; Bernier MO; Spano JP; Lepoutre-Lussey C; Buffet C; Simon JM; Ménégaux F; Tissier F; Leban M; Leenhardt L
    Oncologist; 2016 Jan; 21(1):50-8. PubMed ID: 26675742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Time Series Behavior of Neutrophil-to-Lymphocyte Ratio in Thyroid Cancer Patients on Tyrosine Kinase Inhibitor Therapy.
    Tomoda C; Sugino K; Kitagawa W; Nagahama M; Ito K
    ORL J Otorhinolaryngol Relat Spec; 2021; 83(5):347-353. PubMed ID: 33735904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil-to-lymphocyte ratio as an independent factor for worse prognosis in radioiodine refractory thyroid cancer patients.
    Treistman N; Cavalcante LBCP; Gonzalez F; Fernandes PIW; de Andrade FA; Garcis Alves-Junior PA; Corbo R; Bulzico DA; Vaisman F
    Endocrine; 2023 Jul; 81(1):141-148. PubMed ID: 36905576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRE-ABLATION THYROGLOBULIN AND THYROGLOBULIN TO THYROID-STIMULATING HORMONE RATIO MAY BE ASSOCIATED WITH PULMONARY METASTASES IN CHILDREN WITH DIFFERENTIATED THYROID CANCER.
    Livhits MJ; Pasternak JD; Xiong M; Li N; Gosnell JE; Yeh MW; Chiu HK
    Endocr Pract; 2016 Nov; 22(11):1259-1266. PubMed ID: 27482611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection of progressive disease using thyroglobulin doubling-time in metastatic differentiated thyroid carcinoma treated with radioactive iodine.
    Zhang X; Higuchi T; Tomonaga H; Lamid-Ochir O; Bhattarai A; Nguyen-Thu H; Taketomi-Takahashi A; Hirasawa H; Tsushima Y
    Nucl Med Commun; 2020 Apr; 41(4):350-355. PubMed ID: 32032192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Value of Stimulated Thyroglobulin Before the First Radioactive Iodine Treatment in Metastasis for Differentiated Thyroid Carcinoma.
    Ren L; Zhang C; Shen Y; Mo A; Hu Y; Sun J; Yuan C; Wen W
    Clin Lab; 2021 Jun; 67(6):. PubMed ID: 34107643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer.
    Ozmen S; Timur O; Calik I; Altinkaynak K; Simsek E; Gozcu H; Arslan A; Carlioglu A
    Endocr Regul; 2017 Jul; 51(3):131-136. PubMed ID: 28858848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the Influencing Factors of Tumor Volume, Body Immunity, and Poor Prognosis after
    Tan L; Chen Z; Wang W; Su Y; Wu Z; Yi L; Zheng Z
    Mediators Inflamm; 2023; 2023():8130422. PubMed ID: 37181804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes of distant metastasis from differentiated thyroid carcinoma.
    Huang IC; Chou FF; Liu RT; Tung SC; Chen JF; Kuo MC; Hsieh CJ; Wang PW
    Clin Endocrinol (Oxf); 2012 Mar; 76(3):439-47. PubMed ID: 21950769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma.
    Ito Y; Onoda N; Kudo T; Masuoka H; Higashiyama T; Kihara M; Miya A; Miyauchi A
    In Vivo; 2021; 35(2):1057-1064. PubMed ID: 33622902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma.
    Zhang XY; Sun JW; Qiu ZL; Wang Y; Chen XY; Zhao JH; Luo QY
    Endocrine; 2019 Nov; 66(2):254-265. PubMed ID: 31317522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of radioiodine therapy and prognostic factors of differentiated thyroid cancer patients with pulmonary metastasis: An 8-year retrospective study.
    Wang R; Zhang Y; Tan J; Zhang G; Zhang R; Zheng W; He Y
    Medicine (Baltimore); 2017 May; 96(19):e6809. PubMed ID: 28489758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Postoperative Stimulated Thyroglobulin as Prognostic Factor for Differentiated Thyroid Cancer in Children and Adolescents.
    Zanella A; Scheffel RS; Pasa MW; Dora JM; Maia AL
    Thyroid; 2017 Jun; 27(6):787-792. PubMed ID: 28292215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib.
    Fukuda N; Wang X; Ohmoto A; Urasaki T; Sato Y; Nakano K; Nishizawa M; Yunokawa M; Ono M; Tomomatsu J; Takahashi S
    In Vivo; 2020; 34(2):709-714. PubMed ID: 32111774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Increased Neutrophil-to-Lymphocyte Ratio Predicts Incomplete Response to Therapy in Differentiated Thyroid Cancer.
    Lee F; Yang PS; Chien MN; Lee JJ; Leung CH; Cheng SP
    Int J Med Sci; 2018; 15(14):1757-1763. PubMed ID: 30588200
    [No Abstract]   [Full Text] [Related]  

  • 17. Estimating the Growth Rate of Lung Metastases in Differentiated Thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?
    Song E; Ahn J; Jeon MJ; Lee SM; Lee JH; Kim TY; Baek JH; Kim WB; Shong YK; Kim WG
    Thyroid; 2020 Mar; 30(3):418-424. PubMed ID: 31880976
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic significance of neutrophil-to-lymphocyte ratio for long-term outcomes in patients with poorly differentiated thyroid cancer.
    Oba T; Maeno K; Amitani M; Shimizu T; Ohno K; Ono M; Ito T; Kanai T; Uehara T; Ito KI
    Endocr J; 2021 Nov; 68(11):1329-1336. PubMed ID: 34219074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An enhanced treatment effect can be expected from a higher serum thyroglobulin level after radioactive iodine therapy.
    Choi JH; Lim I; Lee I; Byun BH; Kim BI; Choi CW; Lim SM
    Ann Nucl Med; 2019 Feb; 33(2):128-134. PubMed ID: 30382500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy.
    Miyauchi A; Kudo T; Miya A; Kobayashi K; Ito Y; Takamura Y; Higashiyama T; Fukushima M; Kihara M; Inoue H; Tomoda C; Yabuta T; Masuoka H
    Thyroid; 2011 Jul; 21(7):707-16. PubMed ID: 21649472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.